Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
CPT: Pharmacometrics & Systems Pharmacology|November 12, 2025
Population Pharmacokinetics of Asundexian in People at Risk for Thromboembolic/Cardiovascular EventsAshraf Yassen, Friederike Kanefendt, Jochen Zisowsky, et al.
Journal of Inorganic Biochemistry|April 1, 2011
Enhancing lipophilicity as a strategy to overcome resistance against platinum complexes?Irina Buss, Dirk Garmann, Mathea S Galanski, et al.
Journal of Clinical Pharmacology|April 23, 2022
Population Pharmacokinetics of Nifurtimox in Adult and Pediatric Patients With Chagas DiseaseIbrahim Ince, Klaas Prins, Stefan Willmann, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 17, 2018
Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient PopulationsStefan Willmann, Liping Zhang, Matthias Frede, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 4, 2024
Evaluation of covariate effects in item response theory modelsGustaf J Wellhagen, Ashraf Yassen, Dirk Garmann, et al.
Clinical Pharmacokinetics|June 4, 2021
Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection FractionHauke Ruehs, Dagmar Klein, Matthias Frei, et al.
Clinical Pharmacokinetics|November 17, 2021
Finerenone Dose-Exposure-Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion CriteriaSebastiaan Camiel Goulooze, Nelleke Snelder, Andreas Seelmann, et al.
Clinical Pharmacology and Therapeutics|February 25, 2021
NT-proBNP Qualifies as a Surrogate for Clinical End Points in Heart FailureWalter Schmitt, Hauke Rühs, Rolf Burghaus, et al.
Pageof 3